Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products

2021-08-18T11:55:44+00:00August 18, 2021|Press Releases, Investor Information, Psychedelic News|

We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

  • Clerkenwell | Psyence | Psilocybin

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

2021-07-07T11:41:13+00:00July 7, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.

  • Neil Maresky

Psyence Group Announces Appointment of New Chief Executive Officer

2021-06-28T14:41:30+00:00June 28, 2021|Press Releases, Investor Information|

Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.

JV Signed With Pure Extracts

2021-05-31T09:26:57+00:00March 31, 2021|Press Releases, Investor Information|

Psyence Group Inc. (CSE: PSYG) (“Psyence”), and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) and are pleased to announce the signing of a Letter of Intent (“LOI”) to form a Joint Venture (the “JV”) to develop superior techniques for the extraction of psilocybin from psychedelic mushrooms, as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and its mental health consequences.

Go to Top